Checkpoint Inhibitors Raise Transplant Rejection Risk

A systematic review of 196 transplant patients with skin cancers found high rates of graft rejection and failure under immune checkpoint inhibitor therapy.

Updated on Nov. 11, 2026 in Cancer

Bold flat-color editorial illustration showing a glass IV drip chamber, falling mustard droplets, and a nested cream organ-shaped form on a pale field, evoking transplant risk.
A systematic review of 196 transplant patients with skin cancer found immune checkpoint inhibitors were linked to high rates of graft rejection and failure. AI Illustration. Upload story photo >

A systematic review published in Dermatologic Surgery analyzed systemic therapies for cutaneous malignancies in solid organ transplant recipients. It pooled 101 case reports covering 196 patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

Why it matters

Transplant recipients face elevated skin cancer risk from long-term immunosuppression, so treatment choices carry high stakes. The findings suggest clinicians weigh graft-related dangers when selecting therapy for these patients.

The review pooled 101 case reports covering 196 patients, with checkpoint inhibitors producing complete response in 18.7% and partial response in 20.6%. Because the evidence comes from published case reports rather than controlled trials, the comparative safety of non-checkpoint therapies remains unresolved.

The players

Dermatologic Surgery

A peer-reviewed clinical journal publishing research on dermatologic surgical procedures and related oncology care.

The details

Investigators searched the PubMed/MEDLINE, EMBASE, and Scopus databases and analyzed patient demographics, tumor and transplant characteristics, immunosuppressive regimens, treatment response, and graft outcomes. Among the included patients, 101 had cutaneous squamous cell carcinoma, 83 had melanoma, and 12 had Merkel cell carcinoma.

Timeline

  1. The systematic review was published in 2026 in Dermatologic Surgery.

Health Landscape

Checkpoint inhibitors transformed treatment for advanced melanoma and skin cancers, but transplant recipients were largely excluded from the trials that established them. This review extends that evolving evidence base by quantifying graft rejection and failure risk in this immunosuppressed population.

Transplant recipients with skin cancer should discuss immune checkpoint inhibitor options with their transplant and oncology teams, given the reported graft rejection risk. The findings may shape conversations about balancing cancer treatment against protection of the transplanted organ.

The takeaway

Transplant recipients face a real trade-off when treating skin cancer with immunotherapy, since checkpoint inhibitors were linked to frequent graft rejection. Patients and clinicians should weigh cancer control against organ-protection risks case by case.

Further reading

Explore more on Cancer to see how immunotherapy and transplant medicine intersect.

Source note: This article includes information reported by Oncology Nurse Advisor.